Mechanisms underlying the genetic association between PPP1R3B and Alzheimer's Disease

PPP1R3B 与阿尔茨海默病之间遗传关联的潜在机制

基本信息

  • 批准号:
    10288770
  • 负责人:
  • 金额:
    $ 40.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-08-01 至 2022-07-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Alzheimer’s disease (AD) is the most common cause of dementia, affecting nearly 6 million Americans over the age of 65. The primary risk factor for AD is advanced age, followed by genetic risk variants, and then environmental factors and lifestyle habits. Lifestyle features that contribute to Metabolic Syndrome are highly prevalent in AD patients, including obesity, dyslipidemia, and diabetes. Altered sleep patterns may be one of the earliest signs of progressing AD, and sleep deprivation has been associated with accumulation of both Ab and tau proteins in the brain and cerebrospinal fluid (CSF). Identifying genetic risk factors for Metabolic Syndrome and sleep disturbances could provide novel insights into AD inheritance and risk. A GWAS meta-analysis identified PPP1R3B as a novel putative AD locus, however there is no current understanding of PPP1R3B’s role, cell-type expression, or functional mechanism in AD. Our lab investigates the molecular and biochemical mechanisms by which PPP1R3B is associated with non-alcoholic fatty liver disease (NAFLD) which often occurs in Metabolic Syndrome. Emerging data suggest NAFLD itself may be a risk factor for AD by impeding the clearance of peripheral Ab causing increased brain Ab accumulation. Our current research indicates that hepatic Ppp1r3b deletion in mice recapitulates multiple aspects of Metabolic Syndrome and contributes to NAFLD, and therefore the metabolic consequences of PPP1R3B genetic variation may contribute to the risk of developing AD. Recently, Ppp1r3b was implicated in regulating circadian gene expression. Circadian rhythms influence multiple factors associated with AD, including glucose and lipid metabolism, and sleep-wake cycles. Exploration of gene expression databases revealed that Ppp1r3b is expressed in the brains of mice and humans, and the cell-specific expression patterns suggest that brain Ppp1r3b might have an entirely distinct biochemical mechanism from that described in liver function. Given this unexpected new potential function of Ppp1r3b, we propose to expand our existing research proposal to include a pilot study investigation into the role of Ppp1r3b expression on AD. In this study we aim to investigate two potential avenues of Ppp1r3b expression on AD: Aim 1: Determine the effects of hepatic Ppp1r3b metabolic dysregulation on neuroinflammation and AD-associated cognitive decline using hepatocyte-specific Ppp1r3b KO and overexpression mouse models. Aim 2: Explore the potential involvement of Ppp1r3b in circadian regulation and the relationship to AD, using microglial cell models and examining the effect of whole body Ppp1r3b deletion in mice. Data generated from these pilot experiments will elucidate the roles of hepatocyte and microglia Ppp1r3b expression in AD characteristics in mice. There is potential to establish an entirely novel role for Ppp1r3b in regulating circadian rhythms. These findings will be used to support future research proposals to further examine the PPP1R3B GWAS association with AD.
项目摘要 阿尔茨海默氏病(AD)是痴呆症的最常见原因,影响了近600万美国人 年龄65岁。AD的主要风险因素是高龄,其次是遗传风险变异,然后是 环境因素和生活方式习惯。有助于代谢综合征的生活方式特征很高 在AD患者中普遍存在,包括肥胖症,血脂异常和糖尿病。改变睡眠方式可能是 进展广告的最早迹象和睡眠不足与AB和AB的积累有关 大脑中的tau蛋白和脑脊液(CSF)。确定代谢综合征的遗传危险因素 睡眠障碍可以为AD继承和风险提供新颖的见解。 GWAS荟萃分析将PPP1R3B识别为一个新型的假定广告基因座,但是没有电流 了解PPP1R3B在AD中的作用,细胞类型表达或功能机制。我们的实验室调查了 PPP1R3B与非酒精性脂肪肝病相关的分子和生化机制 (NAFLD)通常发生在代谢综合征中。新兴数据表明NAFLD本身可能是危险因素 通过阻碍清除周围AB的清除,导致大脑AB积累增加。我们的目前 研究表明,小鼠中的肝PPP1R3B缺失概括了代谢综合征的多个方面 并有助于NAFLD,因此PPP1R3B遗传变异的代谢后果可能 有助于发展广告的风险。最近,PPP1R3B在调节昼夜节律中暗示 表达。昼夜节律影响与AD相关的多个因素,包括葡萄糖和脂质 代谢和睡眠效果周期。基因表达数据库的探索表明PPP1R3B是 在小鼠和人类的大脑中表达,细胞特异性表达模式表明大脑 PPP1R3B可能具有与肝功能中描述的完全不同的生化机制。鉴于此 意外的PPP1R3B的新潜在功能,我们建议将现有的研究建议扩展到 包括对PPP1R3B表达在AD的作用的试点研究。在这项研究中,我们的目标是 研究PPP1R3B在AD上表达的两个潜在途径:AIM 1:确定肝PPP1R3B的影响 使用肝细胞特异性的神经炎症和与AD相关的认知下降的代谢失调 PPP1R3B KO和过表达鼠标模型。目标2:探索PPP1R3B的潜在参与 昼夜节律调节和与AD的关系,使用小胶质细胞模型并检查整个的效果 小鼠的身体PPP1R3B缺失。这些试验实验产生的数据将阐明肝细胞的作用 小鼠AD特征中的小胶质细胞PPP1R3B表达。有可能建立一个完全新颖的 PPP1R3B在调节昼夜节律中的作用。这些发现将用于支持未来的研究建议 进一步检查PPP1R3B GWAS与AD的关联。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joseph A. Baur其他文献

Resveratrol for primary prevention of atherosclerosis: Clinical trial evidence for improved gene expression in vascular endothelium
  • DOI:
    10.1016/j.ijcard.2012.09.027
  • 发表时间:
    2013-06-05
  • 期刊:
  • 影响因子:
  • 作者:
    Beamon Agarwal;Matthew J. Campen;Meghan M. Channell;Sarah J. Wherry;Behzad Varamini;James G. Davis;Joseph A. Baur;James M. Smoliga
  • 通讯作者:
    James M. Smoliga
Reducing NAD(H) to amplify rhythms
减少 NAD(H) 以增强节律
  • DOI:
    10.1038/s42255-021-00494-5
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    20.8
  • 作者:
    K. Chellappa;Joseph A. Baur
  • 通讯作者:
    Joseph A. Baur
Swine Models for NAD + Supplementation in Heart Failure
补充 NAD 治疗心力衰竭的猪模型
  • DOI:
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Joseph A. Baur
  • 通讯作者:
    Joseph A. Baur

Joseph A. Baur的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joseph A. Baur', 18)}}的其他基金

Mechanisms and therapeutic potential of blocking the mitochondrial Mg2+ channel Mrs2 in obesity and NAFLD
阻断线粒体 Mg2 通道 Mrs2 在肥胖和 NAFLD 中的机制和治疗潜力
  • 批准号:
    10679847
  • 财政年份:
    2023
  • 资助金额:
    $ 40.62万
  • 项目类别:
HTS to identify compounds that increase NAD+ levels in neurons and muscle cells
HTS 鉴定可增加神经元和肌肉细胞中 NAD 水平的化合物
  • 批准号:
    10665088
  • 财政年份:
    2022
  • 资助金额:
    $ 40.62万
  • 项目类别:
Understanding the roles of cardiac NAD pools and therapeutic effects of precursor supplements in heart failure
了解心脏 NAD 池的作用以及前体补充剂对心力衰竭的治疗作用
  • 批准号:
    10539858
  • 财政年份:
    2022
  • 资助金额:
    $ 40.62万
  • 项目类别:
Understanding the roles of cardiac NAD pools and therapeutic effects of precursor supplements in heart failure
了解心脏 NAD 池的作用以及前体补充剂对心力衰竭的治疗作用
  • 批准号:
    10680576
  • 财政年份:
    2022
  • 资助金额:
    $ 40.62万
  • 项目类别:
HTS to identify compounds that increase NAD+ levels in neurons and muscle cells
HTS 鉴定可增加神经元和肌肉细胞中 NAD 水平的化合物
  • 批准号:
    10618481
  • 财政年份:
    2022
  • 资助金额:
    $ 40.62万
  • 项目类别:
Molecular mechanisms underlying the genetic association between PPP1R3B and hepatic steatosis
PPP1R3B与肝脂肪变性遗传关联的分子机制
  • 批准号:
    10224175
  • 财政年份:
    2018
  • 资助金额:
    $ 40.62万
  • 项目类别:
Targeting NAD Metabolism to Improve Glucose Homeostasis in Obesity and Aging
靶向 NAD 代谢以改善肥胖和衰老过程中的血糖稳态
  • 批准号:
    10288703
  • 财政年份:
    2013
  • 资助金额:
    $ 40.62万
  • 项目类别:
Targeting NAD Metabolism to Improve Glucose Homeostasis in Obesity and Aging
靶向 NAD 代谢以改善肥胖和衰老过程中的血糖稳态
  • 批准号:
    8596305
  • 财政年份:
    2013
  • 资助金额:
    $ 40.62万
  • 项目类别:
Targeting NAD Metabolism to Improve Glucose Homeostasis in Obesity and Aging
靶向 NAD 代谢以改善肥胖和衰老过程中的血糖稳态
  • 批准号:
    8731882
  • 财政年份:
    2013
  • 资助金额:
    $ 40.62万
  • 项目类别:
Molecular Mechanisms of Rapamycin's effects on Health and longevity.
雷帕霉素对健康和长寿影响的分子机制。
  • 批准号:
    8852520
  • 财政年份:
    2013
  • 资助金额:
    $ 40.62万
  • 项目类别:

相似国自然基金

无线供能边缘网络中基于信息年龄的能量与数据协同调度算法研究
  • 批准号:
    62372118
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
CHCHD2在年龄相关肝脏胆固醇代谢紊乱中的作用及机制
  • 批准号:
    82300679
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
颗粒细胞棕榈酰化蛋白FXR1靶向CX43mRNA在年龄相关卵母细胞质量下降中的机制研究
  • 批准号:
    82301784
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
年龄相关性黄斑变性治疗中双靶向药物递释策略及其机制研究
  • 批准号:
    82301217
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
多氯联苯与机体交互作用对生物学年龄的影响及在衰老中的作用机制
  • 批准号:
    82373667
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目

相似海外基金

The Influence of Lifetime Occupational Experience on Cognitive Trajectories Among Mexican Older Adults
终生职业经历对墨西哥老年人认知轨迹的影响
  • 批准号:
    10748606
  • 财政年份:
    2024
  • 资助金额:
    $ 40.62万
  • 项目类别:
The Proactive and Reactive Neuromechanics of Instability in Aging and Dementia with Lewy Bodies
衰老和路易体痴呆中不稳定的主动和反应神经力学
  • 批准号:
    10749539
  • 财政年份:
    2024
  • 资助金额:
    $ 40.62万
  • 项目类别:
Fluency from Flesh to Filament: Collation, Representation, and Analysis of Multi-Scale Neuroimaging data to Characterize and Diagnose Alzheimer's Disease
从肉体到细丝的流畅性:多尺度神经影像数据的整理、表示和分析,以表征和诊断阿尔茨海默病
  • 批准号:
    10462257
  • 财政年份:
    2023
  • 资助金额:
    $ 40.62万
  • 项目类别:
Project 3: 3-D Molecular Atlas of cerebral amyloid angiopathy in the aging brain with and without co-pathology
项目 3:有或没有共同病理的衰老大脑中脑淀粉样血管病的 3-D 分子图谱
  • 批准号:
    10555899
  • 财政年份:
    2023
  • 资助金额:
    $ 40.62万
  • 项目类别:
Sustained eIF5A hypusination at the core of brain metabolic dysfunction in TDP-43 proteinopathies
持续的 eIF5A 抑制是 TDP-43 蛋白病脑代谢功能障碍的核心
  • 批准号:
    10557547
  • 财政年份:
    2023
  • 资助金额:
    $ 40.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了